Alnylam's RNAi drug succeeds in key study, shares soar

(Reuters) - Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.